Business Description
Embecta Corp
NAICS : 325414
SIC : 3841
ISIN : US29082K1051
Total Employee Number:
1,850Description
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | -0.48 | |||||
Debt-to-Equity | -2.43 | |||||
Debt-to-EBITDA | 5.59 | |||||
Interest Coverage | 2.56 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.3 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.3 | |||||
3-Year EBITDA Growth Rate | -6.1 | |||||
3-Year EPS without NRI Growth Rate | -14.9 | |||||
3-Year FCF Growth Rate | -22.9 | |||||
3-Year Book Growth Rate | 10.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -12.25 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.66 | |||||
9-Day RSI | 57.33 | |||||
14-Day RSI | 61.19 | |||||
3-1 Month Momentum % | 4.41 | |||||
6-1 Month Momentum % | -66.52 | |||||
12-1 Month Momentum % | -76.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.68 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.51 | |||||
Days Inventory | 167.39 | |||||
Days Sales Outstanding | 58.54 | |||||
Days Payable | 66.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 9.26 | |||||
Dividend Payout Ratio | 0.23 | |||||
3-Year Dividend Growth Rate | 58.7 | |||||
Forward Dividend Yield % | 0.81 | |||||
5-Year Yield-on-Cost % | 9.26 | |||||
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 59.99 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.03 | |||||
Operating Margin % | 24.33 | |||||
Net Margin % | 8.59 | |||||
EBITDA Margin % | 26.1 | |||||
FCF Margin % | 16.16 | |||||
OCF Margin % | 17.09 | |||||
ROE % | Neg. Equity | |||||
ROA % | 7.8 | |||||
ROIC % | 26.24 | |||||
3-Year ROIIC % | -76.18 | |||||
ROC (Joel Greenblatt) % | 49.16 | |||||
ROCE % | 26.6 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.36 | |||||
Forward PE Ratio | 2.82 | |||||
PE Ratio without NRI | 2.43 | |||||
Price-to-Owner-Earnings | 2.4 | |||||
PS Ratio | 0.29 | |||||
Price-to-Free-Cash-Flow | 1.78 | |||||
Price-to-Operating-Cash-Flow | 1.7 | |||||
EV-to-EBIT | 7 | |||||
EV-to-EBITDA | 5.84 | |||||
EV-to-Revenue | 1.52 | |||||
EV-to-FCF | 9.43 | |||||
Price-to-GF-Value | 0.41 | |||||
Earnings Yield (Greenblatt) % | 14.29 | |||||
FCF Yield % | 58.45 | |||||
Forward Rate of Return (Yacktman) % | 47.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EMBC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Embecta Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,018.7 | ||
| EPS (TTM) ($) | 1.48 | ||
| Beta | 1.1165 | ||
| 3-Year Sharpe Ratio | -0.56 | ||
| 3-Year Sortino Ratio | -0.75 | ||
| Volatility % | 82.46 | ||
| 14-Day RSI | 61.19 | ||
| 14-Day ATR ($) | 0.282126 | ||
| 20-Day SMA ($) | 4.68975 | ||
| 12-1 Month Momentum % | -76.46 | ||
| 52-Week Range ($) | 2.77 - 15.55 | ||
| Shares Outstanding (Mil) | 56.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Embecta Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Embecta Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2027 | 2027-02-11 08:00 | In 168 days | ||
| First quarter earnings conference call for 2027 | 2027-02-05 08:00 | In 162 days | ||
| First quarter earnings results for 2027 | 2027-02-05 | In 161 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-11-25 08:00 | In 90 days | ||
| Annual report for 2026 | 2026-11-25 | In 89 days | ||
| Fourth quarter earnings results for 2026 | 2026-11-25 | In 89 days | ||
| USD 0.010000 Cash Dividend | 2026-08-27 | 4.96 (-0.40%) | ||
| Third quarter earnings conference call for 2026 | 2026-08-07 08:00 | 3.50 (-0.57%) | ||
| Third quarter earnings results for 2026 | 2026-08-07 | 3.50 (-0.57%) | ||
| USD 0.010000 Cash Dividend | 2026-05-28 | 3.29 (+0.30%) |
Show
Entries
Embecta Corp Frequently Asked Questions
What is Embecta Corp(EMBC)'s stock price today?
The current price of EMBC is $4.97. The 52 week high of EMBC is $15.55 and 52 week low is $2.77.
When is next earnings date of Embecta Corp(EMBC)?
The next earnings date of Embecta Corp(EMBC) is 2026-11-25 Est..
Does Embecta Corp(EMBC) pay dividends? If so, how much?
The Dividend Yield %  of Embecta Corp(EMBC) is 9.26% (As of Today), Highest Dividend Payout Ratio of Embecta Corp(EMBC) was 0.25. The lowest was 0.03. And the median was 0.2. The  Forward Dividend Yield % of Embecta Corp(EMBC) is 0.81%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NAS:EMBC
Summers Value Fund
Bearish
2026 Q2
What the manager wrote
Embecta was a detractor in the quarter as shares declined after the company announced the loss of a major pharmacy customer in May and cut its dividend on a diminished cash flow outlook. We underestimated both the risk of losing a longstanding customer and the overall fragility of the business model. Consequently, we exited Embecta following its customer loss and revised outlook, which offset a portion of our short-term gains on Avanos.
Summers Value Fund
Bullish
2026 Q1
What the manager wrote
Embecta sold off after narrowing its fiscal 2026 guidance to the low end of the range. We added to our position on this weakness. Despite following the company for over a decade, we only initiated a position in July of last year. Our interest was driven by a leadership change announced earlier in the year. Dave Picitti, formerly head of Siemens Healthineers’ U.S. business, was appointed CEO in March. Beyond his strong pedigree, his compensation package included performance-based shares that only vested at meaningfully higher share prices, creating clear alignment with shareholders.
Press Release
Articles on Embecta Corp
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers